STOCK TITAN

NovaBay Pharmaceuticals to Present at the Emerging Growth Virtual Conference on May 31, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences acquisition

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, Chief Executive Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, May 31, 2023 at 1:10 p.m. Eastern time (10:10 a.m. Pacific time).

To attend the NovaBay presentation, submit questions in advance of the presentation and receive updates, please register here. Registration for the live webcast will also be accessible from the Events section on the NovaBay website. An archived replay of the webcast following the event will be available on the Company’s website, the Emerging Growth website and the Emerging Growth YouTube Channel.

About the Emerging Growth Conference

The Emerging Growth Virtual Conference is focused on growth companies with strong management teams, innovative products and services, focused strategy, execution and the overall potential for long-term growth. The conference’s audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. More information about the Emerging Growth Conference is available here.

About NovaBay Pharmaceuticals, Inc.:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited.

Socialize and Stay Informed on NovaBays Progress

Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com

Investor Contact

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc.

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Stock Data

4.54M
29.93M
0.04%
3.95%
2.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About NBY

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across